Mallinckrodt and endo plan to combine their generic pharmaceuticals businesses and endo's sterile injectables business after the close of the transaction and intend to separate that business from the combined company at a later date. Endo is providing the following financial guidance for the full year ending december 31, 2025 based on endo's current views, beliefs, estimates and assumptions. Mallinckrodt and endo commenced mailing of the definitive joint proxy statement/prospectus to shareholders of mallinckrodt and endo, respectively, on or about may 12, 2025. Mallinckrodt and endo have merged to create a global, scaled, diversified therapeutics leader Endo takes reports of alleged misconduct very seriously and will investigate them to determine if any law, company policy or aspect of our code of conduct may have been violated.
OPEN
